Professor Terence H Rabbitts (FMedSci, FRS)

Scientific Advisory Board Member

Professor Rabbitts is a molecular biologist, working at the University of Oxford John Radcliffe Hospital, whose examination of the organisation and rearrangement of human genes over the past four decades has helped to shape our understanding of immunity and cancer. Professor Rabbitts was responsible for determining the genetic basis of human antibody diversity, which enables the immune system to fight countless pathogens, and revealed genetic translocations that cause some cancers.He has considerable experience in guiding the commercialisation of cutting edge biotechnology having been the Chairman of the Scientific Advisory Boards of Cambridge Antibody Technology and Quadrant Healthcare until their respective IPOs, a member of the Scientific Advisory Board of Domantis until its acquisition by GSK, Chair of the Medical Advisory Board of Oakes Lyman and he is currently a member of the Scientific Advisory Boards of Oryzon Genomics and of DiThera.Professor Rabbitts worked in Cambridge from 1973-2006 in the MRC Laboratory of Molecular Biology where he was joint Head of the Division of Protein and Nucleic Acid Chemistry together with the Nobel Laureate César Milstein. He was the Director of the Leeds Institute of Molecular Medicine from 2007 to 2010 and is now Professor of Molecular Biology at the Weatherall Institute of Molecular Medicine. He has been awarded the Colworth Medal (1981), the CIBA Prize (1993) and the Clotten Foundation Prize (2015) and was elected as a Member of the European Molecular Biology Organization (EMBO) (1981), a Fellow of the Royal Society (FRS) (1987) and a Founder Fellow of the Academy of Medical Sciences (FMedSci) (1998).